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Abstract
In recent years, there has been increasing interest in
the influence of body composition on oncological pa-
tient outcomes. Visceral obesity, sarcopenia and
sarcopenic obesity have been identified as adverse fac-
tors in cancer patients. Imaging quantification of body
composition such as lean muscle mass and fat distri-
bution is a potentially valuable tool. This review de-
scribes the following imaging techniques that may be
used to assess body composition: dual-energy X-ray
absorptiometry (DXA), computed tomography (CT)
and magnetic resonance imaging (MRI). CT and MRI
are acquired as part of oncological patient care, thus
providing an opportunity to integrate body composition
assessment into the standard clinical pathway and
allowing supportive care to be commenced as appropri-
ate to improve outcome.
Main Messages
• Sarcopenia, sarcopenic obesity and visceral obesity are ad-
verse prognostic factors in cancer patients.
• CT and MRI are the current gold standard in body compo-
sition evaluation.
• Body composition may affect chemotherapy tolerance and
toxicities.
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Introduction
Body composition is an important feature in cancer patients as
it may affect the efficacy and toxicity of chemotherapy, and it
is associated with patient outcomes in terms of functional
status, surgical complication rates, length of hospital stay
(LOS) and overall survival (OS) [1–8]. Assessment of body
composition typically includes the quantitation of fat andmus-
cle mass. In cancer patients, identification of risk factors in-
cluding obesity (an increase in fat mass, in particular visceral
fat mass), sarcopenia (loss of lean muscle mass and function)
and sarcopenic obesity (a combination of loss of lean muscle
mass and visceral obesity) will allow early supportive care
such as dietary and/or physiotherapy interventions to be
implemented.
Obesity
The World Health Organisation body mass index (BMI) is
most commonly used to define obesity [9]. The BMI is calcu-
lated by weight (in kilograms, kg) divided by the height (in
metres, m) squared, where ≥40.0 kg/m2 equates to morbid
obesity, 35.0–39.9 kg/m2 equates to class II obesity, 30.0–
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34.9 kg/m2 equates to class I obesity and 25.0–29.9 kg/m2
refers to overweight individuals [9]. However, associations
between BMI and long-term outcomes and prognosis are
weak in comparison to visceral obesity in cancer patients [5,
6, 10, 11]. In the non-oncological setting, the waist circumfer-
ence (WC) and waist-to-hip ratio (WHR) have been found to
be better discriminators of diabetes and cardiovascular risks
compared to BMI [12, 13]. In the oncological setting,WC and
WHR have been found to be associated with increased risk of
endometrial, oesophagogastric, colorectal and breast cancers
[14–16] although conflicting results were obtained in prostate
and bladder cancers [14, 17]. There is a suggestion that WC
and WHR are associated with inferior oncological outcomes
such as colorectal cancer [18].
Visceral obesity refers more specifically to the excessive
accumulation of visceral fat in the abdominal cavity [10, 11,
19, 20]. There is no definite normal range of visceral adipose
tissue as this varies with age, gender, race and coexisting med-
ical conditions [21]. Nonetheless, in one study that evaluated
visceral adiposity on MRI in a predominantly Caucasian pop-
ulation, the 25th and 75th percentiles of intra-abdominal fat
area were found to be 67.6–140.1 cm2 and 106.3–189.5 cm2
in females and males respectively [22]. Visceral obesity is
calculated as the ratio of the visceral fat area to subcutaneous
fat area, where a ratio greater than 0.4 is considered as visceral
obesity [19]. Visceral fat differs from subcutaneous fat in that
it has a higher number of large adipocytes, more glucocorti-
coid and androgen receptors, and is able to produce more free
fatty acids in comparison to subcutaneous fat [19, 23, 24].
Visceral fat also secretes more bioactive molecules [13] and
is associated with lower insulin sensitivity and higher circu-
lating triglyceride levels [23–25] compared to subcutaneous
fat. The link between visceral obesity and adverse outcomes in
cancer patients may be partly due to increased insulin resis-
tance and its influence on levels of endocrine hormonal secre-
tion, which is also associated cancer progression [26, 27].
Sarcopenia
Sarcopenia literally translates as ‘lack of’ (penia) ‘flesh’
(sarco) in Greek but refers to a loss of muscle mass as well
as function. Sarcopenia may be primary (age-related) or sec-
ondary (associated with reduced activity, poor nutrition, mal-
absorption, endocrine disease, neurodegenerative disorders or
cancer cachexia) [28–31]. Most frequently, sarcopenia has
been defined as an appendicular skeletal muscle mass less
than two standard deviations below the mean of a young
healthy adult group as determined by dual-energy X-ray ab-
sorptiometry (DXA) [28, 30]. The European Society of
Parenteral and Enteral Nutrition Special Interest Group
(ESPEN SIG) proposed that sarcopenia should be diagnosed
based on the presence of two criteria: (1) lowmuscle mass and
(2) impaired muscular function [32]. Due to the significant
variation in body composition between males and females,
sex-specific skeletal muscle index cut-offs (52.4 cm2/m2 and
38.5 cm2/m2 for males and females, respectively) to define
sarcopenia have been proposed in cancer patients and were
shown to be associated with mortality [1]. It is worth bearing
in mind that these definitions were derived from computed
tomography (CT) images obtained at the level of the L3 lum-
bar vertebra. The use of these sex-specific cut-offs has been
supported by an international consensus on the definition of
cancer cachexia in 2011 [33]. It is important to be aware that
sarcopenia may be present even in the absence of weight loss.
For example, Prado et al. showed that 15 % of obese (defined
as BMI ≥30 kg/m2) cancer patients were sarcopenic [1].
Sarcopenic obesity
The combination of sarcopenia and obesity is classified as
sarcopenic obesity. There are subtle variations in the exact
definition of both conditions in various studies, depending
on the method of assessment, although the latter is commonly
defined as BMI ≥30 kg/m2 [34]. Several factors could increase
the risk of sarcopenic obesity [34]. Age-related body compo-
sition changes with progressive decline in muscle mass and/or
strength is a significant risk factor [34, 35]. Hormonal chang-
es, sedentary lifestyle and malnutrition may also occur in the
elderly, contributing to sarcopenic obesity. In addition, adi-
pose tissue secretes pro-inflammatory cytokines and
adipokines, promoting insulin resistance [34, 35], and these
pro-inflammatory markers can contribute towards low muscle
mass and obesity [36].
Cachexia
Cachexia, derived from the Greek words ‘cac’ or bad and
‘hexis’ or condition, is well recognised in patients with chron-
ic illnesses such as cancer, end-stage renal disease, cirrhosis
and chronic obstructive pulmonary disease [30, 33]. The
ESPEN SIG and Cachexia Consensus Working Group have
defined cachexia as a complex metabolic syndrome in chron-
ically ill patients, associated with loss of muscle mass with or
without loss of fatty tissue [32, 37].Many proposed factors are
involved in the development of cachexia such as chronic in-
flammation, increased muscle protein breakdown and insulin
resistance [33, 37]. Although it may be difficult to differentiate
sarcopenia from cachexia particularly in the oncological set-
ting, most cachectic individuals have sarcopenia but not all
sarcopenic patients are cachectic [30, 32].
Assessment of body composition in clinical practice
Various techniques may be used to estimate body composi-
tion. These include bioimpedance analysis (BIA), DXA, CT
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and magnetic resonance imaging (MRI). CT and MRI are
currently considered the gold standards for estimating muscle
mass [30]. Both imaging modalities are obtained as part of the
standard patient care pathway from tumour staging to re-
sponse assessment and surveillance, thus providing an excel-
lent opportunity to integrate body composition assessment
into current patient care. The merits and disadvantages of the
various techniques are summarised in Table 1.
Anthropometrics and bioimpedance analysis
Anthropometric methods such as skin fold thickness by cali-
per measurement, mid arm and calf circumferences have been
used to assess muscle mass. However, these methods are
prone to measurement error with significant interobserver var-
iability and are not recommended for routine diagnosis of
sarcopenia [30].
BIA may be used to estimate fat mass relative to lean body
mass [30]. This involves placing electrodes on the skin, e.g. of
the hand and foot, and measuring the impedance of an applied
low level electric current. The impedance is higher for fat and
bone compared with soft tissue [30]. Impedance measurement
can be affected by hydration status [38] and thus BIA should
be performed under standard conditions to minimise the mea-
surement variation.
A Japanese group has proposed sex-specific equations to
estimate the appendicular skeletal mass using BIA:
0.197×(impedance index)+0.179×(weight) – 0.019 (males)
and 0.221×(impedance index)+0.117×(weight)+0.881
(females) [39]. However, it should be noted that these equa-
tions were derived from the older Japanese population and
have not been validated in other populations or in the
oncological setting. The same group also defined the skeletal
muscle mass index as appendicular skeletal mass/height2 [40].
They classified those with a skeletal muscle mass index less
than 7.09 kg/m2 in males and 5.91 kg/m2 in females as
sarcopenic based on the lowest sex-specific 20 % quintiles
in the healthy population [40].
Dual-energy X-ray absorptiometry
Dual energy X-ray absorptiometry (DXA) exploits the differ-
ence in the attenuation of tissue and bone at different X-ray
energies to measure lean body mass (LBM), fat mass (FM)
and bone mineral mass (BMM) [41], which can be extrapo-
lated to the whole body (Fig. 1). An X-ray source produces a
fan beam at two average X-ray energies, typically 30–40 keV
and 70–90 keV, depending on whether filtration or 70 kV/
140 kV tube voltage switching is used [42]. The typical radi-
ation exposure of a DXA scan is low (0.1 mSv). The X-ray
attenuation and transmission reflect the differences in tissue
thickness, density and the elemental composition of the dif-
ferent compartments. Attenuation increases with tissue thick-
ness and is greater for bone than soft tissue.
DXA is widely used as a clinical tool but is associated with
some limitations. The DXA scan produces a two-dimensional
image; therefore distinction between subcutaneous and viscer-
al adipose tissue cannot be made. Certain assumptions have to
be made, such as the extent of distribution of the fat and
muscle compartments, particularly where there is overlying
bone. As with any quantitative imaging technique, different
manufacturers' software, calibration methods, calculation al-
gorithms and scanners may result in variation in the calculated
estimates of body composition [41, 43–46].
Table 1 Summary of the various techniques used in body composition analysis
Techniques Advantages Disadvantages






Skeletal muscle quality cannot be analysed
Dual-energy X-ray absorptiometry (DXA) Inexpensive
Low radiation exposure (equivalent to
3 days background radiation)
More sensitive than BIA
Lack of portability
Two-dimensional data
Low precision compared to CT and MRI
Distinction between subcutaneous and
visceral adipose tissue cannot be made
Skeletal muscle quality cannot be analysed
Computed tomography (CT) High accuracy and reproducible results
Lean body mass, subcutaneous fat and
visceral fat can be defined
Radiation exposure
More expensive compared to BIA & DXA
Skeletal muscle quality cannot be assessed
Magnetic resonance imaging (MRI) Best spatial resolution and body
mass composition differentiation
No radiation exposure
More expensive compared to BIA and DXA
Longer image acquisition time
Contraindications to MRI may preclude some patients
Skeletal muscle quality cannot be analysed
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Computed tomography and magnetic resonance imaging
CT and MRI are high spatial and contrast resolution cross-
sectional techniques that can provide estimates of lean muscle
mass and adipose tissue as well as fat infiltration within the
skeletal muscle [47–50]. The methods used in the measurement
of cross-sectional body composition are similar for CTandMRI.
The user is usually required to manually delineate the fat or
muscle compartment of interest on a dedicated software platform
(Fig. 2). These regions of interest are then further refined using
specific Hounsfield unit (HU) segmentation thresholds in CT [1]
or grey-level value thresholds in MRI, the latter requiring more
complicated segmentation algorithms [51, 52].
CT
The performance of CT in body composition analysis has
been shown to be superior to DXA [49]. Lean body mass,
subcutaneous and visceral fat mass can be delineated for a
given volume on CT images (Fig. 2) and extrapolated to the
whole body [49]. Several parameters such as the total fat mass,
total lean body mass, fat and lean body mass indices (normal-
ised for stature), subcutaneous fat-to-muscle ratio and
visceral-to-subcutaneous adipose tissue ratio may also be
derived.
Total body fat mass and lean body mass may be defined
using the following equations [49]:
Total body fat mass kgð Þ ¼ 0:042  total adipose tissue at L3 cm2   þ 11:2
Total body lean body mass kgð Þ ¼ 0:3  skeletal muscle at L3 cm2   þ 6:06
The L3 lumbar vertebra landmark is often used in cross-
sectional body composition analysis and is found to corre-
spond to the whole-body tissue measurements [50, 53]. The
field of view at this vertebral level includes the psoas,
paraspinal muscles (erector spinae, quadratus lumborum)
and abdominal wall muscles (transversus abdominus, external
and internal obliques, rectus abdominus), thus making it an
optimal level for skeletal muscle quantification. However,
while the L3 vertebral level is also used to assess fat mass,
the amount of fat will vary according to sex, age and body
level. Thus, there are suggestions that visceral fat should be
derived by obtaining measurements at several different ana-
tomic levels [54] although others have found no significant
clinical impact when correlating visceral fat measured at L2-
L3, L4-L5 and mid waist levels and patient outcome [55].
There is no defined guideline on the image acquisition
parameters that are required for the purpose of cross-
sectional body composition analysis. Thus, for patients who
are undergoing abdominopelvic CT as part their routine diag-
nostic or management algorithm, the following standard CT
acquisition parameters are appropriate: 120 kV, variable mA
with dose modulation, soft tissue reconstruction algorithm,
Fig. 1 Whole-body DXA image showing lean, fat and bone masses
Fig. 2 Subcutaneous fat, visceral
fat and skeletal muscle as
depicted on an axial CT image at
the level of L3 vertebral body
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matrix of 512×512, field of view (FOV) of 30-35 cm and
reconstructed slice thickness 5 mm. However, for patients
undergoing a targeted CT solely for the assessment of body
composition, a limited low-dose axial 10-mm acquisition at
the L3 level may be appropriate: 120 kV, <80 mAs, soft tissue
reconstruction algorithm, matrix of 512×512 and FOVof 30-
35 cm with the advantage that the additional radiation expo-
sure from a limited CT is small and is equivalent to a chest
radiograph [56].
MRI
The major advantage of MRI over CT in body composition
analysis is its lack of radiation exposure. However, the use of
MRI is limited by the local availability and technical expertise.
Nonetheless, clinical MRI scanners are more widely available
now and whole-body MRI techniques are being introduced
that could represent a step forward inMRI assessment of body
composition. MRI has better soft tissue definition particularly
of adipose tissue compared to CT as fat has short T1 and long
T2 proton relaxation times [57] and thus may improve image
segmentation of adipose tissues and skeletal muscle. The ma-
jority of the published literature on the use of MRI has eval-
uated its use in fat mass analysis [52, 58, 59]. MRI estimation
of subcutaneous and intra-abdominal adipose tissues has been
shown to correlate with direct measurement of the correspond-
ing cadaveric tissues [60]. Similar to CT, MRI evaluation at
the level of the L2/3 vertebra was found to be a reliable esti-
mate of fat mass [61].
Improved segmentation of MRI fat and lean body mass
may be produced using a two-point DIXON method for fat/
water separation (Fig. 3) [62, 63]. The information from in-
and out-of-phase gradient echo sequences may be combined.
In the in-phase image, the signal (Sip) represents the sum of fat
(Sf) and water (Sw) signals, i.e. Sip=Sw+Sf, while the out-of-
phase signal represents the difference, i.e. Sip=Sw-Sf.
Averaging of the sum and difference of the in- and out-of-
phase images will result in water and fat signal respectively.
A correction for T2* differences is required as the two images
have different echo times. The two-point DIXON method as-
sumes that the main field B0 homogeneity is perfect.
However, this is not true and refinements such as a three-
point method have been proposed where an in-phase TE se-
quence is used to correct for B0 field homogeneity [64].
A simpler and quicker way of assessing whole-body fat
mass and possibly lean body mass may be feasible with the
advent of whole-body MRI and newer computer-aided
methods of image segmentation [52]. This may have potential
clinical utility as whole-body MRI is currently being evaluat-
ed as a staging modality in different tumour sites such as
multiple myeloma.
A general limitation of these imaging techniques is that
they only provide anatomical information and not functional
information such as muscle function. Thus, these imaging
findings have to be considered in conjunction with formal
assessment of muscle function, particularly in the diagnosis
of sarcopenia [32]. However, there is a suggestion that skeletal
muscle attenuation on CT (Hounsfield units, HU) may poten-
tially be a surrogate for muscle function [65, 66], with reduced
HUwithin skeletal muscle representing increased intramuscu-
lar lipid deposition, which has been observed in those with
neuromuscular disease [65]. This is still an area of research
and no definite HU cut-offs have been reliably identified to
represent reduced muscle function for this to be adopted in the
clinical setting at present. Reduced skeletal muscle attenuation
has also been found to be a negative prognostic factor in
patients with gastrointestinal and respiratory tract cancers
[67].
Clinical applications in oncology
Body composition as a prognosis marker
To our knowledge, there is no published study looking at the
use of MRI body composition assessment in cancer patients.
CT is the most commonly used cross-sectional imaging tech-
nique in this setting and we will be focusing on its use in this
section.
Sarcopenic cancer patients have been shown to have higher
rates of morbidity and mortality [1, 4, 6, 8, 10, 48]. Lieffers
et al. showed that patients with colorectal cancer were at risk
Fig. 3 T1-weighted axial
DIXONMRI images highlighting
(a) fat and (b) water signals at the
level of the L3 vertebral body
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of adverse outcomes after primary colorectal surgery if they
had co-existing sarcopenia [4]. In this study, more than a third
of the patients (39 %) were found to be sarcopenic and they
had an increased length of stay in hospital (mean 16±14 days)
compared to the non-sarcopenic patients (12±10 days, p=
0.038). Post-operative infection risk was also higher in those
with sarcopenia (24 % vs. 13 %, p=0.025). These risks were
more pronounced in patients aged 65 years and above.
However, visceral and subcutaneous adiposities were not sig-
nificant predictors of length of stay and postoperative compli-
cations in a separate study [5].
Moon et al. showed that the visceral fat area-to-
subcutaneous fat area ratio was a significant prognostic factor
in predicting disease-free survival in patients with resectable
colorectal cancer [6]. Those with visceral fat area-to-
subcutaneous fat area ratio >0.5 had shorter disease-free sur-
vival (HR 1.98, 95 % CI 1.02-3.87, p=0.044) although it did
not have a significant impact on overall survival. Similarly,
viscerally obese patients (visceral fat area-to-subcutaneous fat
area ratio ≥0.4) with rectal cancer had poorer disease-free
survival (HR 3.50, 95 % CI 1.12 – 10.17, p=0.09) but there
was no significant difference in overall survival [10]. In con-
trast, body mass index measurements did not correlate with
any survival outcomes [6, 10].
Prado et al. found that sarcopenic obesity was a significant
prognostic factor in patients with gastrointestinal and respira-
tory tract cancers [1]. Patients with coexisting sarcopenic obe-
sity had poorer functional status (p=0.009) and overall sur-
vival (HR 4.2, 95 % CI 2.4–7.2, p<0.0001). These findings
were confirmed in patients with advanced pancreatic cancer
[48]. In this study, sarcopenic obesity was a significant pre-
dictor of reduced overall survival (HR 2.07, 95 % CI=1.23–
3.50, p=0.006).
In contrast to the above positive findings, fat mass and fat-
free mass were not associated with in-hospital mortality or
survival in patients with gastro-oesophageal (GOJ) cancer
treated with neoadjuvant chemotherapy [68]. However, it is
noteworthy that the authors evaluated the prognostic value of
pre-treatment and post-treatment fat-free mass only. Whether
fat mass, as shown in the colorectal cancer population, could
have a greater prognostic impact in GOJ cancer remains un-
clear. In addition, it may be that a reduction in fat-free mass
during treatment may be a more important prognostic factor
than the absolute baseline or post-treatment values as evaluat-
ed in this study.
Treatment implications
In addition to its potential prognostic impact, body composi-
tion may also affect an individual’s tolerance to non-surgical
treatment and could be predictive of treatment toxicity. First,
the use of chemotherapy has been shown to alter body com-
position [69]. Yip et al. showed that fat mass and fat-free mass,
as measured using CT, and weight decreased after neoadju-
vant chemotherapy in patients with oesophageal cancer
(Fig. 4). Similarly, a separate study demonstrated that fat mass
and fat-free mass decreased but the proportion of patients with
sarcopenic obesity increased following neoadjuvant chemo-
therapy in those with GOJ cancers [68].
These body composition changes could have an important
impact on patient’s tolerance to subsequent therapy as
sarcopenia may increase the risk of chemotherapy toxicity
[2, 3, 70]. At present, the body surface area is used to calculate
cytotoxic chemotherapy dosing. As with the bodymass index,
the body surface area is derived using the patient’s height and
weight but is associated with many limitations, particularly in
those with extreme variation in body composition such as
obese patients, leading to under- or overdosing [71]. The risk
of toxicity is higher in female patients as they tend to have a
lower lean bodymass in comparison to their body surface area
[2]. This has led to recent suggestions that lean body mass
may be a better measure to dose chemotherapy on an individ-
ual patient basis [2, 70].
Prado et al. showed that lean body mass was a significant
predictor of dose-limiting toxicities in patients treated with 5-
fluorouracil (5FU) and leucovorin for stage II/III colon cancer
[2]. In this study, females who had more than 20 mg of 5FU/
kg lean body mass were found to have lower cross-sectional
muscle mass and LBM on CT. The authors found that a 5FU/
kg lean body mass cut-off value of less than 20 mg/kg was a
Fig. 4 Axial CT images at the level of L3 vertebra demonstrating progressive sarcopenia in a patient with oesophageal cancer before (a) and after (b)
neoadjuvant chemotherapy. There is a loss of abdominal muscle mass with an increase in visceral fat
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significant predictor of toxicity. This is possibly due to the
differential drug distribution in the different body compart-
ments as hydrophilic drugs are distributed into the lean body
compartment whereas lipophilic drugs are distributed into the
fat compartment. Thus, the size of these compartments, which
could be easily assessed using CT, would affect drug distribu-
tion and therefore toxicity.
The same group also evaluated the impact of sarcopenia on
toxicity and time to progression in patients with metastatic
breast cancer treated with capecitabine [70]. They found that
50 % of sarcopenic patients had grade 2 or greater toxicities
compared to 20 % of non-sarcopenic patients (p=0.03).
Sarcopenic patients also had significantly shorter time to pro-
gression compared to the non-sarcopenic cohort (median
62 days vs. 105 days, p=0.05). Similar observations were also
noted in patients treatedwith sorafenib for metastatic renal cell
carcinoma [3]. In this study, a greater proportion of sarcopenic
male patients experienced dose-limiting toxicities during so-
rafenib therapy compared to the non-sarcopenic patients
(37 % vs. 5 %, p<0.04).
An objective assessment of body composition using cross-
sectional imaging techniques such as CT and MRI has the
potential to complement our current clinical and nutritional
evaluation of patients’ fitness and treatment tolerability. This
information can be readily obtained from standard diagnostic
scans performed during the various stages of patient care.
Nutritional support can then be initiated at an earlier and ap-
propriate stage, which could improve treatment compliance
and clinical outcome.
Other metabolic associations
Although not a direct oncological implication, the metabolic
effect of body composition on cardiovascular risk and mortal-
ity will have an impact on the patients’ overall life expectancy
and tolerance to oncological treatment. Anthropometric indi-
ces such as BMI, WC and WHR are associated with cardio-
vascular risk factors such as hypertension, diabetes and dys-
lipidemia, and cardiovascular disease [12, 72]. Similarly, vis-
ceral adipose tissue as defined on CT has been shown to be
associated with adverse cardiovascular risk factors [25]. These
associations should be considered in order to provide a holistic
approach to patient care.
Future directions
There is sufficient evidence to support the use of body com-
position assessment to direct and improve supportive onco-
logical care such as dietary intervention and physiotherapy
support. As cross-sectional body composition evaluation is
straight forward, this can be introduced with relative ease into
a routine oncology report particularly in high-risk patients
with gastrointestinal cancers or pre-existing gastrointestinal
disease. However, the use of body composition in modifying
cancer therapy requires further research preferably as prospec-
tive clinical studies.
Conclusions
In conclusion, sarcopenia, sarcopenic obesity and visceral
obesity may be associated with negative oncological out-
comes. Imaging assessment of body composition can be read-
ily applied in the clinical setting with the potential to improve
individual nutritional care and perhaps chemotherapy dose
calculation. This personalised cancer management strategy
may reduce treatment-related toxicities and ultimately im-
prove patient outcomes.
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